Molnupiravir

Molnupiravir is a new drug that showed potential in stopping transmission of SARS-CoV-2 in 24 hours. It is an anti-viral drug that is taken orally. Also known as MK-4482/eidd-2801, it was developed by biotechnology firm Ridgeback Biotherapeutics in collaboration with pharmaceutical firm Merck. This is the first time an orally administered drug is rapidly blocking the SARS-CoV-2 transmission. This drug is found to stop replication of the copies of the virus’s RNA in the cell.